Pediatr. praxi. 2009;10(1):26-30

Safety of seven-valent pneumococcal conjugate vaccine

doc. MUDr. Roman Chlíbek Ph.D

Fakulta vojenského zdravotnictví Univerzity obrany, Hradec Králové

The vaccination priorities include vaccination of children against pneumococcal disease in children under 2 years of age. There is still

the only registered 7-valent conjugate pneumococcal vaccine (PCV7). Its reactogenicity and safety was assessed in a number of preand

post-licensure studies. The most common reactions are soreness at the site of vaccination and fever, which may be higher in case

of simultaneous vaccination with other childhood vaccines. In 2009, should be PCV7 vaccination included in the vaccination schedule

in the Czech Republic (CR). There is an importance of the long-term monitoring of the safety of the vaccine after its introduction into

the routine vaccination. There was reported a total number of 23 adverse reactions per 100 thousand doses, of which 8 was identified

as serious in the Czech Republic in 2008. PCV7 is safe, well-tolerated vaccine with adequate reactogenicity in healthy, as well as specific

groups of children at risk.

Keywords: pneumococcus, reactogenicity, safety, conjugate vaccine.

Published: March 1, 2009  Show citation